2022 World Conference on Lung Cancer (ePosters)-EP08.02-112. Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province

EP08.02-112. Precision Treatment of Non-small Cell Lung Cancer Has a Profound Impact on Outcomes in a Canadian Province

Pdf Summary

A study conducted in Alberta, Canada examined the impact of precision treatment on the outcomes of patients with non-small cell lung cancer (NSCLC). The study utilized a database that provided patient-level data on demographic, diagnostic, treatment, and outcomes information for all lung cancer patients in Alberta.<br /><br />The study identified four groups of de novo metastatic NSCLC patients: those treated with targeted therapy against ALK rearrangement, those treated with targeted therapy against EGFR mutation, those treated with cytotoxic chemotherapy as standard of care, and those not treated with systemic anti-cancer therapy.<br /><br />The results showed that patients treated with ALK-targeted therapy had the longest overall survival (OS) compared to the other treatment groups. TKI-treated patients experienced significantly longer survival than those treated with cytotoxic chemotherapy or those not treated with systemic therapy. The use of TKI in patients with detected driver mutations reduced the risk of death by 48% compared to those who received chemotherapy.<br /><br />The study also found that male sex and squamous histology were contributing factors to the differences in OS between treatment strategies. Age did not have a significant impact on survival.<br /><br />The findings highlight the importance of access to biomarker testing and targeted therapy for NSCLC patients. Expanding access to these treatments may significantly improve outcomes, particularly for patients with non-adenocarcinoma NSCLC. The study population in Alberta exhibited OS trends consistent with internationally published real-world data.<br /><br />In conclusion, precision treatment of NSCLC has a profound impact on outcomes, with targeted therapy providing the greatest benefit. The study underscores the need for comprehensive biomarker testing and access to targeted therapy for all eligible patients.

Asset Subtitle

Michelle Liane Dean

Meta Tag

Speaker Michelle Liane Dean

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Alberta

precision treatment

NSCLC

targeted therapy

cytotoxic chemotherapy

overall survival

TKI

driver mutations

biomarker testing

eligible patients